<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010460</url>
  </required_header>
  <id_info>
    <org_study_id>ROXAKI</org_study_id>
    <nct_id>NCT05010460</nct_id>
  </id_info>
  <brief_title>Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting</brief_title>
  <official_title>Roxadustat Reduces the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting: a Multicenter, Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury is a frequent complication after coronary artery bypass grafting (CABG).&#xD;
      Roxadustat is a prolyl hydroxylase inhibitor (PHI) which can stabilize hypoxia-inducible&#xD;
      factor (HIF) and improve the hypoxic tolerance of tissues. Roxadustat has shown effect in&#xD;
      reducing acute kidney injury in animal studies.&#xD;
&#xD;
      This study aims to evaluate the efficacy of administration of Roxadustat before surgery in&#xD;
      the prevention of acute kidney injury after CABG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute kidney injury is a frequent complication after coronary artery bypass grafting (CABG),&#xD;
      with a incidence of 28-38%. Renal ischemia-reperfusion injury is the main mechanism for acute&#xD;
      kidney injury after CABG.&#xD;
&#xD;
      Roxadustat is a kind of prolyl hydroxylase inhibitor (PHI) which can stabilize&#xD;
      hypoxia-inducible factor (HIF) and improve the hypoxic tolerance of tissues. Roxadustat has&#xD;
      shown effect in reducing acute kidney injury in animal studies.&#xD;
&#xD;
      This study aims to evaluate the efficacy of administration of Roxadustat (before surgery) in&#xD;
      the prevention of acute kidney injury after CABG. This is a multicenter, randomized,&#xD;
      double-blind, placebo-controlled study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>acute kidney injury</measure>
    <time_frame>0-48 hours after surgery</time_frame>
    <description>elevation of serum creatinine ≥0.3mg/dl（26.5μmol/L）or ≥ 1.5 times baseline levels within 48 hours post surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>classification of acute kidney injury</measure>
    <time_frame>0-3 days after surgery</time_frame>
    <description>classification of of acute kidney injury based on AKIN criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>0-3 days after surgery</time_frame>
    <description>creatinine, urea, Cystatin-C after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new biomarkers of renal injury</measure>
    <time_frame>immediately after surgery and the first morning after surgery</time_frame>
    <description>serum and urine NGAL，urine TIMP2*IGFBP7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Troponin Subunit I (cTnI)</measure>
    <time_frame>0-3 days after surgery</time_frame>
    <description>peak plasma concentration of cTnI and area under curve (AUC) of cTnI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP)</measure>
    <time_frame>0-3 days after surgery</time_frame>
    <description>plasma concentration of BNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>through study completion, an average of one month</time_frame>
    <description>death during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay and ICU stay</measure>
    <time_frame>through study completion, an average of one month</time_frame>
    <description>length of hospital stay and ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood infusion</measure>
    <time_frame>0-3 days after surgery</time_frame>
    <description>amount of Red blood cells infusion after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>through study completion, an average of one month</time_frame>
    <description>adverse events and severe adverse events during hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Coronary Artery Bypass</condition>
  <arm_group>
    <arm_group_label>Roxadustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roxadustat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo has the same appearance with the experimental drug (Roxadustat).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxadustat</intervention_name>
    <description>orally 100mg every other day for 5-8 days prior to CABG</description>
    <arm_group_label>Roxadustat</arm_group_label>
    <other_name>Evrenzo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally 100mg every other day for 5-8 days prior to CABG</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years old&#xD;
&#xD;
          -  non-emergent CABG and planned cardiopulmonary bypass (CPB)&#xD;
&#xD;
          -  eGFR&gt;15ml/min/1.73m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  malignancy&#xD;
&#xD;
          -  severe liver dysfunction&#xD;
&#xD;
          -  acute kidney injury before randomization&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Qin, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qi Miao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanxi Ai, Doctor</last_name>
    <phone>+861069156874</phone>
    <email>sanxiai@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Qin, Doctor</last_name>
    <phone>+861069156874</phone>
    <email>qinyanbeijing@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huaibin Wang, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Huaibin Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Sanxi Ai</last_name>
      <email>sanxiai@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yan Qin</last_name>
      <email>qinyanbeijing@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yan Qin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi Miao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005 Nov;16(11):3365-70. Epub 2005 Sep 21.</citation>
    <PMID>16177006</PMID>
  </reference>
  <reference>
    <citation>Hill P, Shukla D, Tran MG, Aragones J, Cook HT, Carmeliet P, Maxwell PH. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2008 Jan;19(1):39-46. doi: 10.1681/ASN.2006090998.</citation>
    <PMID>18178798</PMID>
  </reference>
  <reference>
    <citation>Shu S, Wang Y, Zheng M, Liu Z, Cai J, Tang C, Dong Z. Hypoxia and Hypoxia-Inducible Factors in Kidney Injury and Repair. Cells. 2019 Feb 28;8(3). pii: E207. doi: 10.3390/cells8030207. Review.</citation>
    <PMID>30823476</PMID>
  </reference>
  <reference>
    <citation>Kapitsinou PP, Jaffe J, Michael M, Swan CE, Duffy KJ, Erickson-Miller CL, Haase VH. Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury. Am J Physiol Renal Physiol. 2012 May 1;302(9):F1172-9. doi: 10.1152/ajprenal.00667.2011. Epub 2012 Jan 18.</citation>
    <PMID>22262480</PMID>
  </reference>
  <reference>
    <citation>Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, Tao Y, Liang X, Liu Z, Xing C, Chen J, Luo L, Zuo L, Liao Y, Liu BC, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. N Engl J Med. 2019 Sep 12;381(11):1001-1010. doi: 10.1056/NEJMoa1813599. Epub 2019 Jul 24.</citation>
    <PMID>31340089</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute kidney injury</keyword>
  <keyword>coronary artery bypass</keyword>
  <keyword>Roxadustat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>qualified researchers can request access to anonymized individual patient-level data by contacting principle investigator of this study, but this does not mean all requests will be shared by the investigators.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>1 year after the end of this study</ipd_time_frame>
    <ipd_access_criteria>please contact the investigators through email in the time frame</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

